Study of recombinant cytochrome P4502C9 activity with diclofenac by MEKC

被引:16
|
作者
Konecny, Jiri
Jurica, Jan
Tomandl, Josef
Glatz, Zdenek [1 ]
机构
[1] Masaryk Univ, Fac Sci, Dept Biochem, Kamenice 5, CZ-62500 Brno, Czech Republic
[2] Masaryk Univ, Fac Med, Dept Pharmacol, CZ-62500 Brno, Czech Republic
[3] Masaryk Univ, Fac Med, Dept Biochem, CZ-62500 Brno, Czech Republic
关键词
cytochrome P450; diclofenac; drug metabolism; MEKC;
D O I
10.1002/elps.200600560
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Cytochrome P450 2C9 (CYP2C9) is one of the most important isoforms in human liver involved in the metabolism of a large number of therapeutic agents. The aim of this paper is to demonstrate the applicability of CE for the determination of the enzymatic activity of CYP2C9 with diclofenac as a probe substrate. MEKC with SDS as a pseudostationary phase was used for this purpose. Compared to other assays, the MEKC-based method is rapid, can be automated and requires only a small quantity of enzymes and substrate. Moreover the, enzymatic reaction can be monitored with high sensitivity and repeatability even when the reaction mixture is used for the analysis without any pretreatment. The kinetic study on the given enzymatic reaction was also performed since the basic characterization of drug biotransformation generally begins with the enzyme kinetic analysis of metabolite formation. As a result, the Michaelis constant and maximum reaction velocity were evaluated the, values 3.44 +/- 0.45 gM and 19.78 +/- 0.76 nmol . min(-1)nmol(-1), respectively, were in agreement with the literature data. On the other hand, a slight deviation from typical Michaelis-Menten kinetics with a weak positive cooperativity was found at diclofenac concentrations below 2 gM. The same atypical kinetic behavior of CYP2C9 was also observed by other authors.
引用
收藏
页码:1229 / 1234
页数:6
相关论文
共 50 条
  • [1] Warfarin dosing and cytochrome P4502C9 polymorphisms
    Joffe, HV
    Xu, RL
    Johnson, FB
    Longtine, J
    Kucher, N
    Goldhaber, SZ
    THROMBOSIS AND HAEMOSTASIS, 2004, 91 (06) : 1123 - 1128
  • [2] Allelic and functional variability of cytochrome P4502C9
    Bhasker, CR
    Miners, JO
    Coulter, S
    Birkett, DJ
    PHARMACOGENETICS, 1997, 7 (01): : 51 - 58
  • [3] Clinical consequences of cytochrome P4502C9 polymorphisms
    Kirchheiner, J
    Brockmöller, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (01) : 1 - 16
  • [4] Cytochrome P4502C9 activity in end-stage renal disease
    Dreisbach, AW
    Japa, S
    Gebrekal, AB
    Mowry, SE
    Lertora, JJL
    Kamath, BL
    Rettie, AE
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (05) : 475 - 477
  • [5] Tamoxifen inhibits cytochrome P4502C9 activity in breast cancer patients
    Boruban, M. C.
    Yasar, U.
    Babaoglu, M. O.
    Sencan, O.
    Bozkurt, A.
    JOURNAL OF CHEMOTHERAPY, 2006, 18 (04) : 421 - 424
  • [6] The risk of myocardial infarction in patients with reduced activity of cytochrome P4502C9
    Visser, Loes E.
    van Schaik, Ron H. N.
    Danser, Alexander H. Jan
    Hofman, Albert
    Witteman, Jacqueline C. M.
    van Duijn, Cornelia M.
    Uitterlinden, Andre G.
    Pols, Huibert A. P.
    Stricker, Bruno H. Ch.
    PHARMACOGENETICS AND GENOMICS, 2007, 17 (07): : 473 - 479
  • [7] Lornoxicam pharmacokinetics in relation to cytochrome P4502C9 genotype
    Zhang, YF
    Zhong, DF
    Si, DY
    Guo, YJ
    Chen, XY
    Zhou, H
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (01) : 14 - 17
  • [8] Influence of age and cytochrome P4502C9 genotype on the steady-state disposition of diclofenac and celecoxib
    Brenner, SS
    Herrlinger, C
    Dilger, K
    Mürdter, TE
    Hofmann, U
    Marx, C
    Klotz, U
    CLINICAL PHARMACOKINETICS, 2003, 42 (03) : 283 - 292
  • [9] Acenocoumarol pharmacokinetics in relation to cytochrome P4502C9 genotype
    Thijssen, HHW
    Ritzen, B
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 74 (01) : 61 - 68
  • [10] Pharmacokinetics of glimepiride and cytochrome P4502C9 genetic polymorphisms
    Wang, R
    Chen, K
    Wen, SY
    Li, J
    Wang, SQ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (01) : 90 - 92